-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HG-004 in Leber Congenital Amaurosis (LCA)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HG-004 in Leber Congenital Amaurosis (LCA) Drug Details: HG-004 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TRK-950 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TRK-950 in Ovarian Cancer Drug Details: TRK-950 is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-203 in Synovial Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMA-203 in Synovial Sarcoma Drug Details: IMA-203 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGB-3245 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGB-3245 in Colorectal Cancer Drug Details: BGB-3245 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Marstacimab in Hemophilia B (Factor IX Deficiency)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Marstacimab in Hemophilia B (Factor IX Deficiency) Drug Details: Marstacimab (PF-06741086) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TJCLDN-4B in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TJCLDN-4B in Gastric Cancer Drug Details: TJ-033721 is under development for the treatment of gastric...
-
Sector Analysis
![]()
Chronic Lymphocytic Leukemia (CLL) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Chronic Lymphocytic Leukemia (CLL) Market Report Overview The Chronic Lymphocytic Leukemia (CLL) market size for the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) was at $8.4 billion in 2022. The CLL market will register a CAGR of less than 1% from 2022 to 2032. The CLL market research report offers an overview of CLL, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Livmoniplimab in Hypopharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Livmoniplimab in Hypopharyngeal Cancer Drug Details: Livmoniplimab (ABBV-151) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NNZ-2591 in Prader-Willi Syndrome (PWS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NNZ-2591 in Prader-Willi Syndrome (PWS) Drug Details: NNZ-2591 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pelabresib in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pelabresib in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details: Pelabresib (CPI-0610) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemvaleukin Alfa in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemvaleukin Alfa in Small-Cell Lung Cancer Drug Details: Nemvaleukin alfa (ALKS-4230) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemvaleukin Alfa in Epithelial Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemvaleukin Alfa in Epithelial Ovarian Cancer Drug Details: Nemvaleukin alfa (ALKS-4230) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGB-10188 in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGB-10188 in Gastric Cancer Drug Details: BGB-10188 is under development for the treatment of relapsed/refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGB-10188 in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGB-10188 in Diffuse Large B-Cell Lymphoma Drug Details: BGB-10188 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – UI-035 in Cognitive Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.UI-035 in Cognitive DisordersDrug Details:UI-035 is under development for the treatment of cognitive disorders.Report CoverageThe data...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HCP-2102 in Idiopathic (Essential) Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HCP-2102 in Idiopathic (Essential) HypertensionDrug Details:HCP-2102 is under development for the treatment of essential hypertension.Report CoverageThe...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TP-04 in Rosacea
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TP-04 in Rosacea Drug Details:TP-04 is under development for the treatment of rosacea.Report CoverageThe data is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6537 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RG-6537 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details: RG-6537 (RO-7656594, GDC-2992, JMKX-002992) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rapirosiran Sodium in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Rapirosiran Sodium in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Rapirosiran (ALN-HSD) is under development for the treatment of non-alcoholic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RO-7303509 in Systemic Sclerosis (Scleroderma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RO-7303509 in Systemic Sclerosis (Scleroderma) Drug Details:RO-7303509 is under development for the treatment of inflammation and...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.